Thapa Bicky, Lauko Adam, Desai Kunal, Venur Vyshak Alva, Ahluwalia Manmeet S
Fairview Hospital-Cleveland Clinic, Cleveland, OH, USA.
Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
Curr Treat Options Neurol. 2018 Sep 27;20(11):48. doi: 10.1007/s11940-018-0533-2.
Brain metastases are frequent complication of lung cancer and are associated with poor prognosis. Patients with brain metastases secondary to lung cancer have traditionally been managed with surgery and radiation with limited role for systemic chemotherapy. In the past decade, however, this paradigm has shifted largely due to the advent of targeted therapies and immunotherapies, both of which have demonstrated efficacy in the treatment of brain metastases and extracranial disease.
While patients with brain metastases secondary to lung cancer have historically been excluded from trials, recent data suggest efficacy of novel targeted therapies and immunotherapies in these patients. In fact, there are multiple ongoing trials to further evaluate these therapies in this patient profile. Targeted therapies and immunotherapies have the potential to improve outcomes in patients with brain metastases secondary to lung cancer.
脑转移是肺癌常见的并发症，且预后较差。传统上，肺癌继发脑转移的患者接受手术和放疗，全身化疗的作用有限。然而，在过去十年中，由于靶向治疗和免疫治疗的出现，这种模式发生了很大变化，这两种治疗方法在脑转移和颅外疾病的治疗中均显示出疗效。
虽然肺癌继发脑转移的患者历来被排除在试验之外，但最近的数据表明新型靶向治疗和免疫治疗对这些患者有效。事实上，有多项正在进行的试验以进一步评估这些治疗方法在这类患者中的疗效。靶向治疗和免疫治疗有可能改善肺癌继发脑转移患者的预后。
